T
Tae Won Kim
Researcher at Asan Medical Center
Publications - 54
Citations - 2194
Tae Won Kim is an academic researcher from Asan Medical Center. The author has contributed to research in topics: Colorectal cancer & Cancer. The author has an hindex of 17, co-authored 54 publications receiving 1507 citations. Previous affiliations of Tae Won Kim include University of Ulsan.
Papers
More filters
Journal ArticleDOI
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164
Dung T. Le,Tae Won Kim,Eric Van Cutsem,Ravit Geva,Dirk Jäger,Hiroki Hara,Matthew Burge,Bert H. O'Neil,Petr Kavan,Takayuki Yoshino,Rosine Guimbaud,Hiroya Taniguchi,Elena Elez,Salah-Eddin Al-Batran,Patrick McKay Boland,Todd S. Crocenzi,Chloe E. Atreya,Yi Cui,Tong Dai,Patricia Marinello,Luis A. Diaz,Thierry André +21 more
TL;DR: Pembrolizumab is effective with a manageable safety profile in patients with MSI-H/dMMR CRC, and the primary end point was objective response rate by RECIST version 1.1 by independent central review.
Journal ArticleDOI
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.
Timothy J. Price,Marc Peeters,Tae Won Kim,Jin Li,Stefano Cascinu,Paul Ruff,Atilli Satya Suresh,Anne L. Thomas,Sergei Tjulandin,Kathy Zhang,Swaminathan Murugappan,Roger Sidhu +11 more
TL;DR: It is shown that panitumumab is non-inferior to cetuximab and that these agents provide similar overall survival benefit in this population of patients, and small but meaningful differences in the rate of grade 3-4 infusion reactions and differences in dose scheduling can guide physician choice of anti-EGFR treatment.
Journal ArticleDOI
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
Cathy Eng,Tae Won Kim,Johanna C. Bendell,Guillem Argiles,Niall C. Tebbutt,Maria Di Bartolomeo,Alfredo Falcone,Marwan Fakih,Mark Kozloff,Neil H. Segal,Alberto Sobrero,Yibing Yan,Ilsung Chang,Anne Uyei,Louise Roberts,Fortunato Ciardiello,JB Ahn,J. Asselah,S Badarinath,S Baijal,S Begbie,Scott M. Berry,J-L Canon,RG Carbone,Andrés Cervantes,YJ Cha,K Chang,A Chaudhry,E Chmielowska,SH Cho,D Chu,Félix Couture,J Cultrera,David Cunningham,E. Van Cutsem,PJ Cuyle,John Davies,S Dowden,M Dvorkin,Vinod Ganju,Ruth Vera Garcia,Rachel Kerr,TY Kim,K King,J Kortmansky,M Kozloff,Ko Lam,J Lee,AS Lee,B Lesperance,Gabriele Luppi,Brigette B.Y. Ma,Evaristo Maiello,R Mandanas,John Marshall,Gavin Marx,S Mullamitha,M Nechaeva,Jo Park,Nick Pavlakis,CG Ponce,P Potemski,Sherif Raouf,James A. Jr Reeves,N Segal,Salvatore Siena,A Smolin,JO Streb,Andrew Strickland,E Szutowicz-Zielinska,Josep Tabernero,B Tan,Javier Sastre Valera,M Van den Eynde,Philippe Vergauwe,Michael M Vickers,M Womack,M Wroblewska,R. Young +78 more
TL;DR: Overall survival was overall survival in the intention-to-treat population and safety was assessed in the population of patients who received at least one dose of their assigned treatment.
Journal ArticleDOI
Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC).
Johanna C. Bendell,Tae Won Kim,Boon Cher Goh,Jeffrey Wallin,Do-Youn Oh,Sae-Won Han,Carrie B. Lee,Matthew D. Hellmann,Jayesh Desai,Jeremy Lewin,Benjamin Solomon,Laura Q.M. Chow,Wilson H. Miller,Justin F. Gainor,Keith T. Flaherty,Jeffrey R. Infante,Meghna Das-Thakur,Paul Foster,Edward Cha,Yung-Jue Bang +19 more
TL;DR: A Phase Ib study combining cobi (MEK inhibitor) and atezo in patients with advanced solid tumors with lower response rates in microsatellite stable CRCs, finding that targeted inhibition of MEK leads to upregulation of MHC I on tumor cells, induces intratumoral T-cell infiltration and enhances anti-PDL1 activity.
Journal ArticleDOI
Randomized Trial of Postoperative Adjuvant Therapy in Stage II and III Rectal Cancer to Define the Optimal Sequence of Chemotherapy and Radiotherapy: A Preliminary Report
Jung-Hee Lee,Je-Hwan Lee,Jin-Hee Ahn,Hyeseung Bahng,Tae Won Kim,Yoon-Koo Kang,Kyoo-Hyung Lee,Jin-Cheon Kim,Chang-Sik Yu,Jong Hoon Kim,Seung-Do Ahn,Woo-Kun Kim,Sanghee Kim,Jung-Shin Lee +13 more
TL;DR: Early radiotherapy with concurrent chemotherapy after resection of stage II and III rectal cancer demonstrated a statistically significant advantage for disease-free survival compared with late radiotherapy as well as overall survival.